Clinical trials: Intravenous Infusions
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Gastric Cancer
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
Primary Objective: To evaluate the anti-tumor activity of cabazitaxel by assessing objective tumor response rate (ORR) at the recommended dose (RD) when administered as a single agent every 3 weeks in patients with advanced…
- Trial name
- GASTANA (NCT01497964)
- Testing
- cabazitaxel XRP6258
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Sanofi
Healthy
Clinical Trial of Efepoetin Alfa in Healthy Subjects
An open-label, parallel-group, single-center, Phase I study to compare the pharmacokinetic/pharmacodynamic characteristics, safety, and tolerability of a single intravenous administration of Efepoetin Alfa in healthy subjects
- Trial name
- NCT06490939
- Testing
- Efepoetin Alfa
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Ornithine Transcarbamylase Deficiency
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single escalating doses of MRT5201 administered intravenously to subjects with OTC Deficiency (OTCD).
- Trial name
- STEP-OTC (NCT03767270)
- Testing
- MRT5201
- Sponsor
- Translate Bio, Inc.
Healthy
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose of lumicitabine in healthy adult participants.
- Trial name
- NCT03441529
- Testing
- Lumicitabine, Piperacillin/Tazobactam
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
The primary objective of the study is to assess the safety and efficacy of 2 dose groups (PDA001 versus vehicle control) in subjects with active rheumatoid Arthritis.
- Trial name
- NCT01261403
- Testing
- PDA001
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- Celularity Incorporated
Renal Impairment
Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function
This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function.
- Trial name
- NCT00879645
- Testing
- Sodium Sulfide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Pancreatic Cancer
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy.
- Trial name
- NCT00121745
- Testing
- Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Epeius Biotechnologies
Thrombosis
Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function…
- Trial name
- NCT00432770
- Testing
- ARC1779
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Archemix Corp.
Pulmonary Disease, Chronic Obstructive
Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705
GSK233705 is being developed for the treatment of chronic obstructive pulmonary disease. This will be an open-label, dose-ascending study in 7 healthy male subjects to establish well tolerated intravenous doses and an oral dose…
- Trial name
- NCT00500461
- Testing
- GSK233705
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
This is a first-in-human, single-blind, placebo-controlled, single-centre study designed to assess the safety and tolerability of PDNO in healthy male and female subjects.
- Trial name
- NCT04891354
- Testing
- PDNO
- Where
- Sweden
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Attgeno AB
Anesthesia
Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)
The purpose of this study is to compare the infusion rate of Org 9426 following intubating dose of Org 9426 0.6 mg/kg or 0.9 mg/kg in adult surgical patients.
- Trial name
- NCT00988520
- Testing
- Rocuronium bromide, Sevoflurane, Propofol
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in…
- Trial name
- NCT02038920
- Testing
- Vedolizumab
- Where
- 56 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Takeda
Healthy
Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 after continuous intravenous administration of increasing doses in healthy young volunteers
- Trial name
- NCT02222961
- Testing
- BIIR 561 CL
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Unspecified Adult Solid Tumor, Protocol Specific
VNP20009 in Treating Patients With Advanced Solid Tumors
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006254
- Testing
- salmonella VNP20009
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of intoplicine in treating patients who have advanced or…
- Trial name
- NCT00003713
- Testing
- intoplicine
- Where
- 3 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Trial name
- NCT01684150
- Testing
- EPZ-5676
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Epizyme, Inc.
Inflammatory Bowel Disease
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
- Trial name
- NCT01213680
- Testing
- Monofer (iron isomaltoside 1000), Monofer
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Healthy
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers
Study to assess safety, tolerability and pharmacokinetics (PK) of single intravenous (i.v.) doses of BIIB 722 CL
- Trial name
- NCT02224079
- Testing
- BIIB 722 CL
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Safety, Pharmacokinetics
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
- Conditions
- Safety, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT02601625
- Testing
- Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca